| 1.81 -0.01 (-0.55%) | 07-23 15:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical development stage, focused on devising diverse therapeutic strategies that target the underlying origins of various illnesses. One of its key initiatives is the development of MYMD-1, a drug platform centered on a small molecule presently undergoing clinical trials. This molecule works by regulating the immune system to suppress TNF-alpha, a major contributor to chronic inflammation, along with other pro-inflammatory cell-signaling proteins. MYMD-1 is being explored for its potential to delay aging, extend lifespan, manage autoimmune conditions, and treat depression linked to COVID-19. Furthermore, the company is advancing Supera-CBD, a synthetic version of cannabidiol, which aims to address chronic pain, addiction, and epilepsy. MyMD Pharmaceuticals was established in 2014 and its corporate headquarters are situated in Baltimore, Maryland.
Fri, 18 Sep 2026
MyMD Pharmaceuticals stock holds steady as investors watch trial and cash runway - AD HOC NEWS
Fri, 15 May 2026
Mymd Pharmaceuticals (QCLS) Stock Forecast and Price Target 2026 - MarketBeat
Fri, 20 Feb 2026
Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2035 - Insightace Analytic
Wed, 09 Oct 2024
TNF secures investment, CRO services from Prevail Partners - BioXconomy
Wed, 02 Oct 2024
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market - Lelezard
Thu, 22 Aug 2024
TNF Pharmaceuticals to initiate Phase II clinical trials of MYMD-1 - Clinical Trials Arena
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|